Reprint

Schizophrenia Research and Care—Advancements and Challenges

Edited by
December 2023
208 pages
  • ISBN978-3-0365-9816-1 (Hardback)
  • ISBN978-3-0365-9817-8 (PDF)

This book is a reprint of the Special Issue Schizophrenia Research and Care—Advancements and Challenges that was published in

Medicine & Pharmacology
Public Health & Healthcare
Summary

The healthcare system’s ability to diagnose and care for people with schizophrenia has improved in recent decades, as effective pharmacological and psychosocial interventions are now available. However, schizophrenia remains a leading cause of disability and premature mortality.

The utilization of pharmacological and psychosocial interventions in the healthcare system, which have the potential to significantly improve the quality of life for people with schizophrenia, heavily depends on medical professionals completing accurate and comprehensive assessments of patients’ psychopathologies, cognitive profiles, physical health statuses and any environmental factors that may influence them.

This Special Issue reprint on schizophrenia, from the Journal of Clinical Medicine, presents a collection of articles on current approaches to assessment and treatment, as well as new findings and future perspectives of schizophrenia research and care.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
schizophrenia; ERP; mismatch negativity; MMN; P3a; illness duration; real-life functioning; motivation circuits; negative symptoms; RDoC; positive valence system; salience system; schizophrenia; deficit syndrome; schizophrenia; diagnosis; negative symptoms; cognitive function; social skills training; physical comorbidities; childhood abuse; internalized stigma; neutrophil-to-lymphocyte ratio; antipsychotics; schizophrenia; hypothyroidism; inflammatory markers; negative symptoms; expressive deficits; experiential deficits; functioning; quality of life; first psychotic episode; schizophrenia; first episode; emotional processing; social cognition; MCCB; MSCEIT; schizophrenia; negative symptoms; real-world studies; real-world effectiveness; tolerability; treatment adherence; second-generation antipsychotics; long-acting injectable antipsychotics; delusional disorders; psychosis; sex; women; psychopathology; construct; schizophrenia; schizophrenia spectrum; renaming; rethinking; revising; effort expenditure; negative symptoms; recent-onset schizophrenia; persistent negative symptoms; motivation; neuropeptide S; schizophrenia; cognitive functioning; rehabilitation; AEP; QEEG; schizophrenia; antipsychotics; switch; extrapyramidal symptoms; treatment; schizophrenia; negative symptoms; cognitive deficits; self-evaluation of negative symptoms; health-related quality of life